30 years on, AstraZeneca sees healthy future

AstraZeneca has introduced nearly 40 innovative medicines to China, with another 15 expected to be available in the country by 2030.

As early as 2001, the biopharmaceutical company saw the huge potential of China in manufacturing and invested over $100 million in building a supply base in Wuxi, which was then AstraZeneca's largest facility in Asia.

Wuxi is now a strategic city for AstraZeneca, as it features headquarters functions in production, management, R&D, innovation, capital and talent.